These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38395006)

  • 21. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
    Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
    Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.
    Chatterjee S; Perelas A; Yadav R; Kirby DF; Singh A
    Clin Rheumatol; 2023 Mar; 42(3):653-661. PubMed ID: 36271064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials.
    Hoffmann-Vold AM; Volkmann ER; Allanore Y; Assassi S; de Vries-Bouwstra JK; Smith V; Tschoepe I; Loaiza L; Kanakapura M; Distler O
    Lancet Rheumatol; 2022 Oct; 4(10):e679-e687. PubMed ID: 38265966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
    Bruni C; Campochiaro C; de Vries-Bouwstra JK
    Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug.
    Kafle S; Thapa Magar M; Patel P; Poudel A; Cancarevic I
    Cureus; 2021 Jul; 13(7):e16404. PubMed ID: 34414042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nintedanib in systemic sclerosis treatment: a case report.
    Kudsi M; Tarcha R; Khalayli N
    J Med Case Rep; 2024 Feb; 18(1):110. PubMed ID: 38388392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Clinical Profile and Safety of Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Subgroup Analysis of Interstitial Lung Disease Data From an Interstitial Lung Disease (ILD) Specialty Clinic in India.
    Behera AK; Sharma P; Tg R; Kumar V; Pati SK; Sinha K
    Cureus; 2024 Jul; 16(7):e65579. PubMed ID: 39192903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
    Richter P; Cardoneanu A; Dima N; Bratoiu I; Rezus C; Burlui AM; Costin D; Macovei LA; Rezus E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study.
    Ninagawa K; Kato M; Tsuneta S; Ishizaka S; Ujiie H; Hisada R; Kono M; Fujieda Y; Ito YM; Atsumi T
    Rheumatology (Oxford); 2023 Jul; 62(7):2550-2555. PubMed ID: 36458921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
    Khanna D; Lescoat A; Roofeh D; Bernstein EJ; Kazerooni EA; Roth MD; Martinez F; Flaherty KR; Denton CP
    Arthritis Rheumatol; 2022 Jan; 74(1):13-27. PubMed ID: 34313399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study.
    Sato R; Handa T; Matsumoto H; Kubo T; Hirai T
    BMC Pulm Med; 2019 Dec; 19(1):247. PubMed ID: 31842848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interstitial Lung Disease in Systemic Sclerosis: A Single-center Retrospective Analysis.
    Yayla ME; Balcı G; Torgutalp M; Eroğlu DŞ; Dinçer ABK; Gülöksüz EGA; Sezer S; Yüksel ML; Ateş A; Turgay TM; Kınıklı G
    Curr Rheumatol Rev; 2022; 18(2):150-156. PubMed ID: 34517806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    Vonk MC; Guillén-Del-Castillo A; Kreuter M; Avis M; Marzin K; Mack SR; Wind S; Gahlemann M
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):81-89. PubMed ID: 34664183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
    Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity.
    Cutolo M; Gotelli E; Montagna P; Tardito S; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S
    Arthritis Res Ther; 2021 Aug; 23(1):205. PubMed ID: 34344444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.